fusidic acid has been researched along with ketoconazole in 17 studies
| Studies (fusidic acid) | Trials (fusidic acid) | Recent Studies (post-2010) (fusidic acid) | Studies (ketoconazole) | Trials (ketoconazole) | Recent Studies (post-2010) (ketoconazole) |
|---|---|---|---|---|---|
| 1,742 | 117 | 344 | 6,202 | 706 | 1,269 |
| 1,742 | 117 | 344 | 149 | 0 | 120 |
| Protein | Taxonomy | fusidic acid (IC50) | ketoconazole (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 2.6 | |
| 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial | Homo sapiens (human) | 0.34 | |
| 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial | Mus musculus (house mouse) | 0.36 | |
| Bile salt export pump | Homo sapiens (human) | 3.44 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | 1.5811 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 6.7 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 4.6771 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.2303 | |
| Steroid 21-hydroxylase | Homo sapiens (human) | 6.655 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.06 | |
| Aromatase | Homo sapiens (human) | 1.4111 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Rattus norvegicus (Norway rat) | 2.0802 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 5.425 | |
| Cholesterol side-chain cleavage enzyme, mitochondrial | Rattus norvegicus (Norway rat) | 3.32 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 1.067 | |
| Cytochrome P450 2A2 | Rattus norvegicus (Norway rat) | 0.456 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.38 | |
| Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | 0.4519 | |
| Translocator protein | Rattus norvegicus (Norway rat) | 3.76 | |
| Cytochrome P450 7A1 | Rattus norvegicus (Norway rat) | 1.2975 | |
| Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | 0.5179 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 3.8 | |
| Thromboxane-A synthase | Homo sapiens (human) | 2.165 | |
| Gonadotropin-releasing hormone receptor | Rattus norvegicus (Norway rat) | 2 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.531 | |
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.0078 | |
| Cytochrome P450 4F2 | Homo sapiens (human) | 1.6 | |
| 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial | Homo sapiens (human) | 0.4144 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.9036 | |
| Lanosterol 14-alpha demethylase | Homo sapiens (human) | 0.19 | |
| Cytochrome P450 7A1 | Mus musculus (house mouse) | 1.2975 | |
| Lanosterol 14-alpha demethylase | Rattus norvegicus (Norway rat) | 0.083 | |
| Epoxide hydrolase 1 | Homo sapiens (human) | 0.04 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.774 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.2535 | |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | 0.04 | |
| Sterol 14-alpha demethylase | Trypanosoma cruzi strain CL Brener | 0.014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (52.94) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Pagliano, F | 1 |
| Bianchi, G | 1 |
| Pellerano, S | 1 |
| Pazzaglia, A | 2 |
| Gini, M | 1 |
| Franchi, G | 1 |
| Marras, F | 1 |
| Scremin, S | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
1 review(s) available for fusidic acid and ketoconazole
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 trial(s) available for fusidic acid and ketoconazole
| Article | Year |
|---|---|
Use of a combination of an anti-inflammatory steroid, an antibacterial agent and an antifungal in dermatological practice.
Topics: Administration, Topical; Adolescent; Adult; Aged; Betamethasone; Clinical Trials as Topic; Clobetasol; Drug Therapy, Combination; Female; Fusidic Acid; Humans; Ketoconazole; Male; Middle Aged; Skin Diseases | 1985 |
15 other study(ies) available for fusidic acid and ketoconazole
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Treatment of skin diseases of mixed aetiology in outpatients.
Topics: Administration, Topical; Adolescent; Adult; Aged; Bacterial Infections; Beclomethasone; Child; Dermatitis, Contact; Dermatomycoses; Drug Combinations; Female; Fusidic Acid; Humans; Ketoconazole; Male; Middle Aged; Skin Diseases; Skin Diseases, Infectious | 1986 |
Multivalent treatment of skin diseases in infants and young children.
Topics: Administration, Topical; Bacterial Infections; Beclomethasone; Child; Child, Preschool; Dermatomycoses; Diaper Rash; Drug Therapy, Combination; Female; Fusidic Acid; Humans; Infant; Ketoconazole; Male; Skin Diseases | 1985 |
Clinical results obtained with a combination of an anti-inflammatory steroid, an antibacterial agent and an antifungal in dermatological outpatient practice.
Topics: Administration, Topical; Adolescent; Adult; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Antifungal Agents; Beclomethasone; Drug Combinations; Female; Fusidic Acid; Humans; Ketoconazole; Male; Middle Aged; Skin Diseases | 1985 |
Use of a combination of an anti-inflammatory corticosteroid, an antibacterial agent and an antifungal in the local post-operative treatment of cutaneo-mucosal diseases following cryosurgery.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Antifungal Agents; Beclomethasone; Child; Combined Modality Therapy; Cryosurgery; Drug Combinations; Erythema; Female; Fusidic Acid; Humans; Ketoconazole; Male; Middle Aged; Skin Diseases | 1985 |
Treatment of dermatological conditions with a combination of an antibacterial agent, an antifungal agent and an antiinflammatory steroid.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Child; Child, Preschool; Clobetasol; Dermatologic Agents; Drug Therapy, Combination; Female; Fusidic Acid; Humans; Infant; Ketoconazole; Male; Middle Aged; Skin Diseases | 1985 |
Therapeutic effects and tolerance of an extempore combination of an antibacterial, an anti-inflammatory, and an antimycotic cream in skin diseases of various origins.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Antifungal Agents; Child; Child, Preschool; Clobetasol; Drug Combinations; Female; Fusidic Acid; Humans; Ketoconazole; Male; Middle Aged; Skin Diseases | 1985 |
Therapeutic usefulness of a corticosteroid, antibacterial and antifungal combination in skin diseases of various origins.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Infective Agents, Local; Antifungal Agents; Clobetasol; Drug Combinations; Female; Fusidic Acid; Humans; Ketoconazole; Male; Middle Aged; Skin Diseases, Infectious | 1985 |
Treatment of skin diseases of various origins with a multi-action drug combination.
Topics: Administration, Topical; Adolescent; Adult; Aged; Beclomethasone; Drug Combinations; Female; Fusidic Acid; Humans; Ketoconazole; Male; Middle Aged; Skin Diseases; Time Factors | 1985 |